Sagimet Biosciences

Denifanstat (SB2640-CLIN-011) is a small-molecule therapeutic candidate developed by Sagimet Biosciences for metabolic dysfunction-associated fatty liver disease (MASLD). The program advanced to Phase 3 clinical development; however, the trial was terminated as of May 15, 2025. The specific mechanism of action, molecular target, and rationale for termination have not been disclosed. Denifanstat represents Sagimet's clinical-stage effort in the MASLD space, a disease area with significant unmet medical need given the rising prevalence of fatty liver disease globally and limited approved pharmacotherapies. The termination of the Phase 3 program marks a significant setback for this candidate, though the company continues to evaluate other assets in its pipeline, including the Phase 2 program TVB-2640. Regulatory approval status and future development plans remain undisclosed.

MASLD affects a substantial and growing patient population worldwide, driven by obesity, metabolic syndrome, and type 2 diabetes epidemiology. The disease progresses from simple steatosis to steatohepatitis (MASH), fibrosis, and cirrhosis, creating significant morbidity and mortality risk. Currently, no disease-modifying pharmacotherapies are approved specifically for MASLD, making the indication a high-priority therapeutic target for pharmaceutical development. The termination of denifanstat's Phase 3 program removes one candidate from the competitive landscape, potentially affecting Sagimet's commercial strategy in MASLD. The competitive environment includes other small-molecule approaches such as ALN-PNP (Regeneron UK Limited, Phase 2) and Sagimet's own TVB-2640 (Phase 2), indicating active industry interest in metabolic liver disease. The failure of denifanstat to advance highlights the clinical and regulatory challenges inherent in MASLD drug development, where efficacy endpoints, patient stratification, and long-term safety remain areas of scientific debate. Successful MASLD therapies represent substantial commercial opportunities given the large addressable patient population and lack of approved alternatives.

Denifanstat is a small-molecule therapeutic candidate. The specific mechanism of action, molecular target, and route of administration have not been disclosed. The program is classified as a small-molecule modality, consistent with oral or parenteral delivery typical of this drug class. Related therapies in development for MASLD include other small-molecule approaches targeting metabolic pathways implicated in hepatic lipid accumulation and inflammation. First approval status and patent information are not yet disclosed.

Regulatory approval status for denifanstat has not been disclosed. FDA, EMA, PMDA (Japan), and NMPA (China) approval history and current regulatory interactions are not yet disclosed. The Phase 3 trial termination as of May 15, 2025, indicates the program did not progress to regulatory filing. Future regulatory plans, if any, remain undisclosed.

The termination of denifanstat's Phase 3 program represents a significant clinical setback for Sagimet Biosciences in the MASLD space. Without disclosed reasons for termination, the decision likely reflects one or more of the following: insufficient efficacy, safety concerns, or strategic portfolio reallocation. The company's continued investment in TVB-2640 (Phase 2) suggests Sagimet remains committed to MASLD but may have deprioritized denifanstat in favor of alternative mechanisms or formulations. The competitive landscape for MASLD remains active, with multiple sponsors pursuing small-molecule therapies, indicating sustained industry confidence in the indication despite individual program failures. Future catalysts for Sagimet include TVB-2640 Phase 2 data readouts and any strategic announcements regarding denifanstat or alternative MASLD programs. The denifanstat termination underscores the clinical and regulatory challenges inherent in MASLD drug development, where patient stratification, disease heterogeneity, and endpoint selection remain contentious issues.